Inclusion Criteria:

- No clinically significant adverse events thought to be due to etanercept (TNFR:Fc)
during previous treatment.

- Negative serum pregnancy test not more than 14 days before the first dose of study
drug in females of childbearing potential.

- No more than one NSAID at a dose not greater than the maximum recommended dose and
stable for at least two weeks prior to administration of etanercept (TNFR:Fc).
Exclusion Criteria: - Previous receipt of TNFR:Fc (p55), antibody to TNF, anti-CD4
antibody, or diphtheria IL-2 fusion protein.

- Receipt of investigational drugs or biologics (other than TNFR:Fc [p75]) within 1
month prior to the first dose of etanercept (TNFR:Fc) in this study.

- Receipt of DMARDs or methotrexate (except patients from 16.0014) within two weeks
prior to the first dose of etanercept (TNFR:Fc) in this study.

- Receipt of cyclophosphamide within six months prior to the first dose of (etanercept
(TNFR:Fc) in this study.

- Receipt of cyclosporin within two weeks prior to the first dose of etanercept
(TNFR:Fc) in this study.

Start Date:

Completion Date:

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.